The prime example is using poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of adults with advanced breast, ovarian, and prostate cancers in the context of germline mutations in DDR genes, such as BRCA1, BRCA2, ATM, or PALB235–37. This evidence concerns the gene BRCA2 and prostate cancer.